Impact of Ribosome Activity on SARS-CoV-2 LNP – Based mRNA Vaccines by Evangelos Tsiambas, Evangelos Tsiambas, Evangelos Tsiambas, Aristeidis Chrysovergis, Vasileios Papanikolaou, Nicholas Mastronikolis, Vasileios Ragos, Anna Batistatou, Dimitrios Peschos, Nikolaos Kavantzas, Andreas C. Lazaris, Efthimios Kyrodimos

“…In order to confront this emergency situation, many pharmaceutical companies focused on the design and development of efficient vaccines that are considered necessary for providing a level of normalization in totally affected human social-economical activity worldwide. …”
Get full text

Organization of Hygienic Monitoring of Working Area Air Pollution by Particulates in Pharmaceutical Industries (Review) by I. A. Pozharnov, A. S. Simakov, A. A. Shatilina, G. V. Ramenskaya

“…The use of highly active substances of various origins in the pharmaceutical industry exposes employees working directly with active pharmaceutical substances (APS) in manufacturing facilities to risks. Although pharmaceutical companies follow occupational safety requirements, such as the use of personal protective equipment (PPE), the manipulation of highly toxic substances in specially dedicated indoor facilities, etc., the impact of risk factors on the health of workers must be regularly assessed and monitored. …”
Get full text

Financial and Economic Costs of the Elimination and Eradication of Onchocerciasis (River Blindness) in Africa. by Young Eun Kim, Elisa Sicuri, Fabrizio Tediosi

“…To realize cost-savings, policymakers should keep empowering community volunteers, and pharmaceutical companies would need to continue drug donation. …”
Get full text

Linking sustainable use policies to novel economic incentives to stimulate antibiotic research and development by Ursula Theuretzbacher, Christine Årdal, Stephan Harbarth

“…These policies would be targeted not only at the innovating pharmaceutical companies in exchange for the reward payments, but also at governments in countries which receive the novel antibiotics at reasonable prices due to the reward payment. …”
Get full text

Improving access to medicines via the Health Impact Fund in India: a stakeholder analysis by Patrick McMullan, Vamadevan S. Ajay, Ravi Srinivas, Sandeep Bhalla, Dorairaj Prabhakaran, Amitava Banerjee

“…The Health Impact Fund (HIF) is a novel proposal whereby pharmaceutical companies would be paid based on the measured global health impact of their drugs. …”
Get full text

Opportunities and Threats of the Legally Facilitated Performance-Based Managed Entry Agreements in Slovakia: The Early-Adoption Perspective by Petra Hospodková, Klára Gilíková, Miroslav Barták, Elena Marušáková, Aleš Tichopád

“…A roughly one-hour open interview was conducted on a sample of 12 stakeholders in the following groups: representatives of the Ministry of Health, health-care providers, pharmaceutical companies and others, including a health insurance company. …”
Get full text

The influence of socio-demographic characteristics on attitudes towards prophylactic vaccination in Poland by Alicja Włodarska, Mariusz Gujski, Jarosław Pinkas, Filip Raciborski

“…At the same time, nearly a third (31%) of the subjects agreed with the statement that vaccination is promoted mainly because this is in the interests of pharmaceutical companies, and more than a fifth (22%) of the respondents believed that vaccines for children can cause serious developmental disorders, including autism. …”
Get full text

Stress and motivation of cell processing operators: A pilot study of an online questionnaire survey by Mitsuru Mizuno, Yoshimi Sugahara, Daisuke Iwayama, Noe Miyashita, Hisako Katano, Ichiro Sekiya

“…A survey questionnaire was distributed to 64 operators in 31 CPFs, including universities, clinics, and pharmaceutical companies, from December 2021 to February 2022. …”
Get full text

Biosafety management strategy based on multiple linear regression model by Zhao Chao, Xiao Zhanpeng, Zhang Te, Xiao Na

“…Arithmetic means to score and significance of 100 enterprises (schools, pharmaceutical companies, hospitals, and other types of these four major types) under the multiple linear regression model. …”
Get full text

Drug shortages in Saudi Arabia: Root causes and recommendations by Yazed S. Alruthia, Monira Alwhaibi, Mashal F. Alotaibi, Shatha A. Asiri, Bushra M. Alghamdi, Ghadah S. Almuaythir, Wejdan R. Alsharif, Hala H. Alrasheed, Yahya A. Alswayeh, Abdulaziz J. Alotaibi, Mohammad Almeshal, Saleh N. Aldekhail, Abdulrahman Alhusaini, Sulaiman A. Alrashed, Ali M. Alrumaih, Mohammed A. Dahhas, Mohammed A. Alghamdi, Mohammad S. Aleheidib, Mohamed H. Alhaidari, Jameel A. Alharbi, Aws Alshamsan

“…The main domestic causes of drug shortages that were explored in this study included poor medication supply chain management, lack of government regulation that mandates early notification of drug shortages, a government procurement policy that does not keep pace with the changes in the pharmaceutical market, low profit margins of some essential drugs, weak and ineffective law-violation penalties against pharmaceutical companies and licensed drug importers and distributors, and overdependence on drug imports. …”
Get full text

A quantitative systems pharmacology approach, incorporating a novel liver model, for predicting pharmacokinetic drug-drug interactions. by Mohammed H Cherkaoui-Rbati, Stuart W Paine, Peter Littlewood, Cyril Rauch

“…All pharmaceutical companies are required to assess pharmacokinetic drug-drug interactions (DDIs) of new chemical entities (NCEs) and mathematical prediction helps to select the best NCE candidate with regard to adverse effects resulting from a DDI before any costly clinical studies. …”
Get full text

Dissociation by steroids of eosinophilic inflammation from airway hyperresponsiveness in murine airways by McCluskie Kerryn, Woodman Paul, Battram Cliff H, Birrell Mark A, Belvisi Maria G

“…These data suggest that eosinophilia is not associated with AHR and questions the rationale that many pharmaceutical companies are adopting in developing low-molecular-mass compounds that target eosinophil activation/recruitment for the treatment of asthma.…”
Get full text

Addressing the affordability of cancer drugs: using deliberative public engagement to inform health policy by Colene Bentley, Stuart Peacock, Julia Abelson, Michael M. Burgess, Olivier Demers-Payette, Holly Longstaff, Laura Tripp, John N. Lavis, Michael G. Wilson

“…These factors put considerable strain on the sustainability of health systems worldwide, sparking public debate among clinicians, pharmaceutical companies, policy-makers and citizens on issues of affordability and equity. …”
Get full text

Decentralized clinical trials (DCTs): A few ethical considerations by Carlo Petrini, Chiara Mannelli, Luciana Riva, Sabina Gainotti, Gualberto Gussoni

“…The CoViD-19 pandemic has caused a significant increase in DCT: a survey shows that 76% of pharmaceutical companies, device manufacturers, and Contract Research Organizations adopted decentralized techniques during the early phase of the pandemic. …”
Get full text

The environmental impact of inhaler replacement: A carbon footprint and economic calculation of the National Database of Health Insurance Claims in Japan by Kazuya Nagasaki, Yuki Kaji, Yoshiki Wada, Takafumi Sasaki

“…Nevertheless, collaborative efforts between physicians, patients, and pharmaceutical companies are necessary to reduce GHG emissions.…”
Get full text

Discretization and Analysis of HIV-1 and HTLV-I Coinfection Model with Latent Reservoirs by Ahmed M. Elaiw, Abdualaziz K. Aljahdali, Aatef D. Hobiny

“…This may draw the attention of scientists and pharmaceutical companies to create new treatments that prolong the latency period.…”
Get full text

Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters by Hyosun Kim

“…Methods The FDA’s warning letters and NOVs, which were issued to pharmaceutical companies over a 10-year period (2005 to 2014) regarding online promotional activities, were content-analyzed. …”
Get full text

Policies and practices in Nigeria’s pharmaceutical sector: A mixed methods exploration of stakeholders’ perspectives on strategic reforms by Obi Peter Adigwe

“…Majority of the study participants indicated the need for collaboration between pharmaceutical companies, research institutes and the petrochemical industry. …”
Get full text

Financing repurposed drugs for rare diseases: a case study of Unravel Biosciences by Bechara Abouarab, Christian Bazarian, Zied Ben Chaouch, Andrew W. Lo, Guillermo Mourenza Gonzalez, Richard Novak, Frederic Vigneault

“…Conclusions Repurposing existing compounds offers important advantages that could help early-stage biotech startups better align their business and financing issues with their scientific and medical objectives, enter a space that is not occupied by large pharmaceutical companies, and accelerate the validation of their drug development platform.…”
Get full text

Lights and Shadows on the Therapeutic Use of Antimicrobial Peptides by Denise Bellotti, Maurizio Remelli

“…However, the shortage of available antimicrobial drugs in clinical use is also caused by the high costs involved in developing and marketing new drugs without an adequate guarantee of an economic return; therefore, the pharmaceutical companies have reduced their investments in this area. …”
Get full text